JCXH 211
Alternative Names: JCXH-211Latest Information Update: 11 Jul 2024
At a glance
- Originator Immorna
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Glioblastoma
Most Recent Events
- 08 Jul 2024 US FDA approves IND application for JCXH 211 in Solid tumours
- 08 Jul 2024 Immorna Biotherapeutics plans a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Late-stage disease) in USA (IV)
- 07 Jul 2024 Adverse events data from preclinical studies in Solid tumours released by Immorna Biotherapeutics